Anterior epistaxis accounts for 80–90% of all nosebleeds, typically originating from Kiesselbach's plexus in Little's area on the anteroinferior nasal septum. [1] Lifetime prevalence is approximately 60%, with ~6% of affected individuals seeking medical attention. [1] Management is straightforward in most cases and follows a systematic, escalating approach. [1]
The following figure illustrates the nasal vascular anatomy, including Kiesselbach's area where most anterior bleeds originate:
1. History
- Onset and duration: Spontaneous vs. provoked; which side; how long bleeding has lasted
- Quantity: Estimate volume (teaspoons/cups); blood swallowed or spat out
- Frequency: First episode vs. recurrent; pattern of recurrence (unilateral vs. bilateral)
- Triggers: Digital trauma (nose picking), dry air/low humidity, nose blowing, recent URI, nasal spray use, facial/nasal trauma [1][3]
- Associated symptoms: Nasal obstruction, rhinorrhea, facial pain, foul smell (foreign body in children)
- Medication history: Anticoagulants (warfarin, DOACs), antiplatelets (aspirin, clopidogrel), intranasal steroids, NSAIDs [4]
- Important negatives: No bleeding from other sites (gums, GI, GU), no easy bruising, no hemoptysis, no hematemesis
2. Alarm Features
- Hemodynamic instability: Tachycardia, hypotension, syncope, pallor, diaphoresis → hemorrhagic shock (rare but critical) [1]
- Bilateral bleeding or bleeding from the mouth → suspect posterior source or airway compromise [1]
- Recurrent unilateral epistaxis with nasal obstruction → concern for nasal/nasopharyngeal mass (including juvenile nasopharyngeal angiofibroma in adolescent males) [4]
- Bleeding refractory to 20 min of compression + first-line interventions → escalate to packing, ENT consultation [1]
- Supratherapeutic INR (>4.5) → higher risk of admission and prolonged stay [4]
- Signs of coagulopathy: Petechiae, mucosal bleeding at multiple sites, large ecchymoses
- Traumatic epistaxis with altered mental status, facial deformity → evaluate for facial fractures and TBI [5]
3. Medications
Contributing medications
- Warfarin, DOACs (rivaroxaban, apixaban, dabigatran, edoxaban) [4]
- Antiplatelets: aspirin, clopidogrel, prasugrel, ticagrelor [4]
- Intranasal corticosteroids (chronic mucosal irritation)
- NSAIDs, herbal supplements (ginkgo, garlic, fish oil)
Treatment medications
- Topical oxymetazoline (Afrin): First-line vasoconstrictor; superior hemostasis rates (~71%) vs. TXA or epinephrine-lidocaine in one trial. Avoid in patients with significant cardiovascular disease [1][6]
- Topical tranexamic acid (TXA): 500 mg in 5 mL on pledget for 10–15 min; improves bleeding control, reduces rebleeding, shortens ED stays; especially useful in patients on anticoagulants/antiplatelets [4][7]
- Silver nitrate sticks (25–75%): Chemical cautery for identified bleeding point [4]
- Topical lidocaine or tetracaine: For anesthesia prior to cautery [4]
Cautions
- Avoid topical vasoconstrictors in patients with uncontrolled hypertension, severe CAD, or recent MI [1]
- Avoid TXA in patients with active thromboembolic disease [7]
- In the absence of life-threatening bleeding, initiate first-line treatments before reversing anticoagulation or withholding anticoagulant/antiplatelet medications [4]
4. Diet
- Hydration: Adequate oral hydration helps maintain mucosal moisture
- Avoid hot liquids, spicy foods, and alcohol for 24–48 hours post-episode (promote vasodilation)
- Long-term: Humidification of home environment; saline nasal spray for mucosal moisture [8]
5. Review of Systems
- HEENT: Nasal obstruction, rhinorrhea, foul nasal discharge, facial pain/pressure, oral bleeding
- Hematologic: Easy bruising, prolonged bleeding from cuts, heavy menses, GI bleeding
- Cardiovascular: Hypertension symptoms, chest pain, palpitations
- Dermatologic: Telangiectasias on lips, tongue, fingertips (HHT) [1]
- Constitutional: Weight loss, night sweats, fatigue (malignancy, blood dyscrasia)
6. Collateral History and Family History
- Family history of bleeding disorders: von Willebrand disease (up to 5–10% of children with recurrent epistaxis may have undiagnosed vWD), hemophilia [3]
- Family history of HHT: Autosomal dominant; prevalence 1 in 5000; mucocutaneous telangiectasias and AVMs [1]
- Social context: Intranasal drug use (cocaine → mucosal erosion, septal perforation), occupational exposures, dry environments
- In children: Confirm nose-picking behavior, foreign body insertion history
7. Risk Factors
- Local: Digital trauma, dry air/low humidity, intranasal medication use, nasal septal deviation, prior nasal surgery, allergic rhinitis, URI [1][3]
- Systemic: Hypertension (most common comorbidity, found in 24–64% of epistaxis patients), atherosclerosis [4]
- Medications: Anticoagulants and antiplatelets (15% of ED epistaxis patients on long-term anticoagulation) [4]
- Hematologic: Coagulopathies, thrombocytopenia, leukemia, hepatic disease, renal disease [9]
- Hereditary: HHT, von Willebrand disease, hemophilia [1][3]
- Age: Bimodal distribution — common in children (peak ~7 years) and adults >60 years [10]
- Environmental: Cold/dry climates, winter months, airborne pollutants [3]
8. Differential Diagnosis
- Posterior epistaxis: More common in elderly/hypertensive patients; bleeding from both nares or into oropharynx; harder to control [1]
- Nasal/nasopharyngeal mass: Unilateral recurrent epistaxis + obstruction → pyogenic granuloma, inverted papilloma, squamous cell carcinoma, juvenile nasopharyngeal angiofibroma (adolescent males) [4]
- Nasal foreign body (children): Unilateral epistaxis + foul rhinorrhea [4]
- Coagulopathy: vWD, hemophilia, ITP, DIC, liver failure — bleeding at multiple sites [3]
- HHT: Recurrent, bilateral, spontaneous epistaxis with telangiectasias [1]
- Traumatic: Nasal fracture, facial fracture, septal hematoma, basilar skull fracture (CSF rhinorrhea) [5]
- Cocaine use: Mucosal necrosis, septal perforation
- Granulomatosis with polyangiitis (GPA): Nasal crusting, saddle-nose deformity, epistaxis
9. Past Medical History
- Prior epistaxis episodes and treatments received
- Nasal or sinus surgery
- Hypertension, cardiovascular disease, liver disease, renal disease
- Known bleeding disorders
- Malignancy (hematologic or sinonasal)
- Chronic rhinosinusitis, allergic rhinitis, septal deviation/perforation
10. Physical Exam
Vital signs
Focused exam
- Anterior rhinoscopy (nasal speculum + headlight): Identify bleeding site on anterior septum (Kiesselbach's plexus); remove clot by suction or gentle nose blowing first [4]
- Oropharynx: Check for blood trickling down posterior pharynx (suggests posterior source)
- Skin: Petechiae, ecchymoses, telangiectasias (lips, tongue, fingertips → HHT)
- Face: Nasal deformity, septal hematoma (fluctuant, bluish swelling — must drain urgently), facial fracture signs
- In children: Use otoscope for anterior nasal exam; evaluate for foreign body [4]
11. Lab Studies
- Routine labs are NOT indicated for uncomplicated, first-time anterior epistaxis that responds to simple measures
- Check if clinically indicated:
- CBC: If significant blood loss, recurrent episodes, or concern for hematologic disorder
- PT/INR: Patients on warfarin (INR >4.5 associated with worse outcomes) [4]
- PTT: If on heparin or suspected coagulopathy
- Type and screen/crossmatch: If hemodynamically unstable or significant hemorrhage
- BMP: If concern for renal disease contributing to platelet dysfunction
- Coagulation screening is appropriate for patients with anticoagulant use or suspected bleeding diathesis [11]
- Note: PT/INR and PTT do not reliably reflect anticoagulation degree for patients on DOACs [4]
12. Imaging
- Imaging is NOT routinely indicated for uncomplicated anterior epistaxis [12]
- CT paranasal sinuses: Consider for recurrent epistaxis, suspected nasal mass, or inflammatory disease; CT adds little for first-time severe epistaxis (pathology found in only 1.9% of first-time cases) [13]
- CT angiography: Preferred for vascular assessment and interventional planning in severe/posterior/refractory bleeding [12]
- MRI: When soft tissue or intracranial extension of a mass is suspected [12]
13. Special Tests
- Anterior rhinoscopy: First-line diagnostic tool; identifies bleeding site in most anterior cases [4]
- Nasal endoscopy (rigid or flexible): Indicated for recurrent bleeding despite treatment, recurrent unilateral bleeding, or concern for posterior source or mass; localizes bleeding site in 87–93% of cases [4]
- Point-of-care ultrasound: Limited role; not standard for epistaxis
- von Willebrand panel: Consider in children with recurrent idiopathic epistaxis (5–10% may have undiagnosed vWD) [3]
- Curaçao criteria: Clinical diagnostic criteria for HHT (spontaneous recurrent epistaxis, mucocutaneous telangiectasias, visceral AVMs, first-degree relative with HHT)
14. ECG
- Not routinely indicated for uncomplicated anterior epistaxis
- Obtain ECG if: Significant blood loss with tachycardia, known cardiac history, hemodynamic instability, or considering use of topical vasoconstrictors (epinephrine) in patients with cardiac disease
- Watch for: Sinus tachycardia (blood loss), ischemic changes in elderly patients with significant hemorrhage
15. Assessment
Anterior epistaxis is the most common form of epistaxis, arising from Kiesselbach's plexus in >80% of cases. [1] It is typically self-limited and responds to simple measures. The cause is idiopathic in 70–80% of cases. [10]
Severity stratification: [9]
- Mild: Self-resolves with pressure alone (~24% of ED presentations) [6]
- Moderate: Requires cautery and/or packing
- Severe: Hemodynamic instability, need for reversal agents, surgical/radiologic intervention (~15% of ED presentations) [9]
Atypical presentations warranting further evaluation: Recurrent unilateral bleeding, bleeding refractory to standard measures, associated nasal obstruction, adolescent males with profuse unilateral bleeding. [4]
16. Treatment Plan
Stepwise, escalating approach: [1][4]
- Direct pressure: Firm, continuous pinch of the lower third (soft part) of the nose for 15–20 minutes, leaning forward, mouth breathing [1][5]
- Topical vasoconstrictor: Oxymetazoline-soaked pledget or cotton ball placed in the affected naris. Alternative: topical TXA (500 mg/5 mL on pledget for 10–15 min) [6-7]
- Cautery (if bleeding site identified):
- Anesthetize with topical lidocaine or tetracaine [4]
- Silver nitrate (chemical cautery) or electrocautery — electrocautery is more effective [4]
- Avoid bilateral cautery at the same site to prevent septal perforation [4]
- Anterior nasal packing (if bleeding site not identified or cautery fails):
- Resorbable packing (e.g., Surgicel, Gelfoam): Preferred in patients on anticoagulants — no removal needed, lower rebleed risk [1]
- Nonresorbable packing (e.g., Merocel, Rapid Rhino): Leave in place 24–72 hours; requires follow-up for removal [4]
- Refractory bleeding → ENT consultation for:
- Posterior packing
- Endoscopic sphenopalatine artery ligation (success >90%) [4]
- Endovascular embolization [4]
Anticoagulation management: Initiate first-line treatments before considering reversal. For life-threatening bleeding, refer to reversal agents per medication class. [4]
17. Disposition
Discharge criteria (majority of anterior epistaxis)
- Bleeding controlled with pressure, cautery, or packing
- Hemodynamically stable
- No signs of significant blood loss
- Reliable follow-up available (especially if nonresorbable packing placed) [1]
Observation/Admission criteria
- Hemodynamic instability or significant blood loss requiring transfusion
- Posterior packing in place (risk of hypoxia, aspiration)
- Supratherapeutic INR (>4.5) with ongoing bleeding [4]
- Refractory bleeding requiring surgical or interventional radiology consultation [4]
- Significant comorbidities (severe cardiovascular disease, coagulopathy) with ongoing or recurrent bleeding [1]
ENT consultation triggers
- Bleeding refractory to anterior packing
- Suspected posterior source
- Recurrent unilateral epistaxis (concern for mass) [4]
- Need for nasal endoscopy or surgical intervention [4]
18. Follow Up / Return Precautions
Follow-up timing
- If nonresorbable packing placed: Return in 24–72 hours for removal [4]
- If cautery performed: ENT or PCP follow-up in 1–2 weeks
- Recurrent epistaxis: ENT referral for nasal endoscopy [4]
Return precautions — advise patients to return immediately for:
- Recurrent heavy bleeding not controlled by 20 minutes of firm pressure
- Bleeding from both nostrils or into the throat
- Lightheadedness, dizziness, or fainting
- Difficulty breathing
- Fever (if packing in place — concern for toxic shock syndrome or sinusitis)
Patient counseling
- Avoid nose blowing, straining, heavy lifting, hot beverages, and bending forward for 24–48 hours
- Use saline nasal spray or petroleum jelly (Vaseline) to keep nasal mucosa moist [4][8]
- Humidify home environment, especially in winter
- Avoid digital trauma (nose picking)
- If on anticoagulants: do not stop medications without consulting prescribing physician [4]
Expected recovery: Most anterior epistaxis resolves with a single intervention. Rebleeding occurs in a minority of cases and is more common in patients on anticoagulants or with posterior sources. [9-10]
References
1. Epistaxis. — Seikaly H. The New England Journal of Medicine. 2021.
2. Epistaxis. — Schlosser RJ. The New England Journal of Medicine. 2009.
3. Interventions for Recurrent Idiopathic Epistaxis (Nosebleeds) in Children. — Qureishi A, Burton MJ. The Cochrane Database of Systematic Reviews. 2012.
4. Clinical Practice Guideline: Nosebleed (Epistaxis). — Tunkel DE, Anne S, Payne SC, et al. Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery. 2020.
5. 2024 American Heart Association and American Red Cross Guidelines for First Aid. — Hewett Brumberg EK, Douma MJ, Alibertis K, et al. Circulation. 2024.
6. Comparison of the Efficacy of Oxymetazoline, Tranexamic Acid, and Epinephrine-Lidocaine Combination in the Treatment of Epistaxis. — Çelik T, Altun M, Kudu E, et al. The American Journal of Emergency Medicine. 2025.
7. Stopping the Flow: Tranexamic Acid as an Adjunct to Anterior Epistaxis Management - An Invited Commentary. — Nathan RS, Setzen M. American Journal of Otolaryngology. 2026.
8. Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. — Faughnan ME, Mager JJ, Hetts SW, et al. Annals of Internal Medicine. 2020.
9. Risk Factors and Management Outcomes in Epistaxis: A Tertiary Centre Experience. — Hughes JM, Teh BM, Hart CJ, Gibbs HH, Aung AK. ANZ Journal of Surgery. 2023.
10. Tranexamic Acid for Patients With Nasal Haemorrhage (Epistaxis). — Joseph J, Martinez-Devesa P, Bellorini J, Burton MJ. The Cochrane Database of Systematic Reviews. 2018.
11. Initial Assessment in the Management of Adult Epistaxis: Systematic Review. — Khan M, Conroy K, Ubayasiri K, et al. The Journal of Laryngology and Otology. 2017.
12. ESR Essentials: Imaging in Nasal Obstruction and Epistaxis-Practice Recommendations by the European Society of Head and Neck Radiology. — Péporté ARJ, Vassallo E, Preda L, Beale T, Hirvonen J. European Radiology. 2026.
13. Computed Tomography Findings in Patients With Primarily Unknown Causes of Severe or Recurrent Epistaxis. — van Horn N, Faizy TD, Schoenfeld MH, et al. PloS One. 2019.